Dapagliflozin

Approximately 52% of patients with HF are categorized as those with a preserved ejection fraction. Hospitalizations in this patient population are continuing to increase.

The American Diabetes Association announced updates to its 2022 Standards of Medical Care in Diabetes to reflect new data on cardiovascular outcomes with diabetes and kidney disease and use of SGLT2 inhibitors.

Healio and Cardiology Today have compiled a list of the most-read news in cardiology of May 2022.

At Heart Rhythm 2022, researchers reported that applying an artificial intelligence to an Apple Watch ECG can detect left ventricular dysfunction in a nonclinical setting.

Topline findings from the phase 3 DELIVER trial show dapagliflozin significantly reduced risk for CV death or worsening HF compared with placebo in adults HF with mildly reduced or preserved ejection fraction, AstraZeneca announced.

Among patients hospitalized with COVID-19, dapagliflozin was well tolerated and did not increase risk of AKI in patients, according to data published in the Clinical Journal of the American Society of Nephrology.

The SGLT2 inhibitor dapagliflozin safely reduced risk for worsening HF or CV death among adults with HF with reduced ejection fraction compared with placebo regardless of frailty status, researchers reported.

Combination therapy with a GLP-1 receptor agonist and an SGLT2 inhibitor may provide better weight-loss benefits than a single agent for women with polycystic ovary syndrome and obesity, according to study data.

An analysis of data showed patients with chronic kidney disease and type 2 diabetes who were or were not prescribed mineralocorticoid receptor antagonists saw reductions in major adverse kidney outcomes after taking dapagliflozin.

For patients with chronic kidney disease, dapagliflozin slowed long-term decreases in the eGFR.